Igyxos and Selexis Enter Service Agreement to Advance Igyxos’ First-In-Class Monoclonal Antibody for…
Selexis SA and Igyxos announced that they have entered into a service agreement to develop Igyxos’ first-in-class monoclonal antibody (mAb) drug candidate for the treatment of human…
Read More...
Read More...